Last reviewed · How we verify
real word drugs (real-word-drugs)
real word drugs (generic name: real-word-drugs) is a real word drugs drug developed by Pfizer Inc.. It is currently in preclinical development.
real word drugs
Sirolimus is a hydrolytic enzyme drug that targets methotrexate, and it is being studied for the treatment of Peripheral Artery Disease, Atherosclerosis, and other conditions. It is administered via a Neo sirolimus coated PTA balloon catheter, such as the Xtreme Touch, in clinical trials.
-
Baseline preclinical → approval rate
+5.0pp
Industry-wide preclinical drugs reach approval ~5% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2036–2040 | — |
| EMA | EU | 2037–2041 | +0.7 yr |
| MHRA | GB | 2037–2041 | +0.7 yr |
| Health Canada | CA | 2037–2042 | +0.9 yr |
| TGA | AU | 2037–2042 | +1.2 yr |
| PMDA | JP | 2037–2042 | +1.5 yr |
| NMPA | CN | 2038–2043 | +2.3 yr |
| MFDS | KR | 2037–2042 | +1.4 yr |
| CDSCO | IN | 2037–2043 | +1.8 yr |
| ANVISA | BR | 2038–2043 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | real-word-drugs |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | real word drugs |
| Therapeutic area | Other |
| Phase | preclinical |
Approved indications
Pipeline indications
- Familial Mediterranean Fever (FMF ) — preclinical
Common side effects
Key clinical trials
- Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan (N/A)
- A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory (Phase 3)
- Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and R (N/A)
- Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit (Phase 4)
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders (N/A)
- An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Coli (N/A)
- Litfulo Capsules Special Investigation (N/A)
- Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- real word drugs CI brief — competitive landscape report
- real word drugs updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about real word drugs
What is real word drugs?
How does real word drugs work?
Who makes real word drugs?
What is the generic name of real word drugs?
What drug class is real word drugs in?
What development phase is real word drugs in?
Related
- Drug class: All real word drugs drugs
- Manufacturer: Pfizer Inc. — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing